La sclérose en plaques est une maladie auto-immune qui touche le cerveau et qu'on ne sait toujours pas vraiment guérir. La mise sur le marché d'un nouveau traitement vient d'être validée par les autorités sanitaires européennes.

Aging is a complex biological process involving progressive decline in physiological function, driven by accumulation of cellular and molecular damage across multiple levels. While researchers have identified key hallmarks of aging including genomic instability, telomere attrition, and mitochondrial dysfunction, clinical practice has traditionally relied on chronological age as the primary metric for understanding aging. However, chronological age oversimplifies this multifactorial phenomenon and fails to account for significant individual variations in the aging process. This reliance stems from the historical absence of reliable biomarkers and measurement methods. Consequently, chronological age serves as an imperfect proxy for functional capacity and health vulnerability, as individuals of the same age often exhibit markedly different physiological states and health outcomes. Understanding the causal mechanisms underlying aging requires moving beyond chronological age toward more sophisticated, personalized measures of biological aging.

I cannot provide a summary for this article because the content provided only shows a redirect page without the actual article text. To write an accurate and informative professional summary, I would need access to the full article content discussing the relationship between Epstein-Barr virus and multiple sclerosis. Please provide the complete article text, and I will be happy to create a comprehensive 100-word summary suitable for a professional intelligence platform.

Multiple sclerosis research is advancing significantly through new diagnostic methods and treatment approaches. Scientists are developing disease-modifying therapies and exploring experimental stem cell treatments to better manage inflammation, protect nerves, and repair myelin damage, particularly for progressive MS patients. Genetic research has revealed that specific gene variants can influence MS progression rates and disease severity. A recent 2023 study found that individuals carrying certain genetic markers required mobility assistance approximately 3.7 years earlier than those without these variants, suggesting genes play a crucial role in the brain's capacity to manage MS damage. Diagnosis continues to rely on MRI imaging, blood tests, and spinal fluid analysis. While stem cell therapy remains experimental and not yet widely available, ongoing research into genetic factors and innovative treatment modalities offers promising potential for improving patient outcomes and understanding disease mechanisms.

Researchers have developed a groundbreaking approach to reverse cellular aging by resetting the epigenetic clock through partial epigenetic reprogramming (PER). Unlike previous full reprogramming methods that transformed adult cells into blank slates but risked uncontrolled differentiation, PER rejuvenates aged cells while preserving their identity and function. This technique works by erasing epigenetic changes accumulated over time without compromising cellular characteristics. Life Biosciences is advancing this technology with ER-100, entering the first-in-human study for treating optic neuropathies. The therapeutic potential extends beyond vision restoration, promising broader clinical applications in addressing age-related cellular decline and potentially revolutionizing regenerative medicine.

Despite major advances in therapy for multiple sclerosis (MS) patients, substantial unmet needs remain, particularly regarding the prevention of disability progression and the treatment of progressive and aggressive forms of the disease. While early use of high-efficacy therapies has improved inflammatory disease control, their impact on long-term neurodegeneration is limited, and therapeutic options for progressive MS remain scarce. Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a highly effective escalation strategy for selected patients with aggressive, inflammatory MS.

Researchers from Yale School of Medicine have identified a genetically driven immunologic mechanism linking Epstein-Barr virus (EBV) infection to multiple sclerosis development. This collaborative study, involving international institutions, elucidates how genetic factors predispose individuals to MS through EBV-triggered immune responses. The findings represent a significant advancement in understanding the molecular basis of MS pathogenesis, potentially opening new therapeutic avenues for prevention and treatment. By establishing this mechanistic link between viral infection and autoimmune disease, the research contributes valuable insights into how environmental and genetic factors converge in neurological disease development.

This comprehensive review examines how innate immunity fundamentally regulates adaptive immune responses through multiple interconnected mechanisms. The authors elucidate three primary pathways: remodeling of antigen presentation and costimulation, cytokine-mediated T helper cell polarization, and metabolic-epigenetic programming associated with trained immunity. The framework identifies three critical regulatory dimensions of innate immune signaling: insufficient activation impairs pathogen control and adaptive priming, excessive persistent activation drives autoimmune inflammation, and type 2-biased signaling promotes allergic responses. By integrating molecular signaling, cell crosstalk, metabolic regulation, and epigenetic remodeling, this review provides a unified understanding of how innate immune dysfunction contributes to adaptive immune dysregulation in infection, autoimmunity, and allergic diseases, while identifying therapeutic targets including interferon pathways, inflammasomes, and metabolic programs.

Multiple sclerosis, once thought to develop in an isolated brain, is increasingly recognized as influenced by complex environmental interactions. Despite skull and blood-brain barrier protection, the brain constantly adapts to external factors affecting disease development and progression. Research identifies several environmental contributors to MS risk, including viral infections like Epstein-Barr virus, vitamin D deficiency from limited sun exposure, and gut microbiota composition. Additional factors include dietary patterns, obesity, hormonal fluctuations, smoking, stress, air pollution, and temperature variations. The disease predominantly affects women and represents the leading cause of disability in young adults outside traumatic injuries, with higher prevalence in regions distant from the equator. Understanding these environmental-genetic interactions is crucial for comprehending MS pathogenesis and developing preventive strategies.

Aging represents a complex biological process characterized by progressive functional decline that drives the incidence of age-related diseases, including neurodegeneration, metabolic disorders, and cardiovascular conditions. Current therapeutic strategies target core aging hallmarks such as cellular senescence, metabolic dysfunction, epigenetic alterations, and mitochondrial impairment. Three primary approaches show considerable promise: senolytics eliminate senescent cells, senomorphics inhibit senescence-associated secretory phenotype, and senoreversion rejuvenates senescent cells through epigenetic reprogramming. Metabolic interventions, including caloric restriction mimetics like spermidine and α-ketoglutarate, enhance mitochondrial function and activate autophagy, demonstrating lifespan extension in preclinical models. Collectively, these emerging interventions facilitate the transition toward precision longevity medicine while leveraging artificial intelligence to accelerate therapeutic discovery through multiomics integration.

Imagine if multiple sclerosis (MS) became as rare as polio. It sounds absurd. MS is chronic, unpredictable, and devastating. We’ve spent decades throwing immunosuppressants, monoclonal antibodies, and remyelination therapies at it. But no matter how advanced our treatments have become, they all manage the disease, not the cause. That might be about to change.

Researchers from the Garvan Institute of Medical Research have conducted an unprecedented analysis of over 1.25 million blood cells from nearly 1,000 participants to elucidate why women experience higher rates of autoimmune diseases. Using single-cell RNA sequencing, the team identified over 1,000 genetic switches in immune cells that function differently based on sex. These variations in gene expression indicate that inflammatory pathways responding to threats are more active in women, increasing susceptibility to conditions such as lupus and multiple sclerosis. The findings underscore the critical importance of incorporating sex-based considerations into immune system research and clinical treatment development. This pioneering study addresses a significant gap in medical research by examining individual cell-level differences rather than averaging gene activity across mixed cell populations, potentially revolutionizing our understanding of sex-specific disease mechanisms.

Researchers from the Garvan Institute and UNSW Sydney have identified over 1,000 genetic switches that function differently between female and male immune cells, providing crucial insights into why women are significantly more susceptible to autoimmune diseases such as lupus and multiple sclerosis. The study, published in The American Journal of Human Genetics, reveals that female immune systems exhibit higher inflammatory pathway activity, making them more prone to mistakenly attacking healthy body tissues. These findings underscore a critical gap in medical research, which has historically focused on male cohorts, and emphasize the necessity of considering sex differences in understanding disease mechanisms and developing effective treatments.

Recent research has established Epstein-Barr virus as a pivotal factor in multiple sclerosis pathogenesis. Dr. Micah Luftig presents mechanistic insights into the EBV-MS relationship, highlighting its significance for clinical risk stratification and early intervention strategies. The emerging evidence suggests that EBV-targeted therapeutic approaches may fundamentally reshape future MS treatment protocols. Understanding the molecular mechanisms linking viral infection to neuroinflammatory cascade activation is crucial for developing preventive and therapeutic interventions. These findings have substantial implications for clinicians managing MS patients and may inform personalized medicine approaches based on individual EBV serostatus and immune profiles.

Researchers found that CUX2 neurons are especially sensitive to damage caused by inflammation. In diseases like MS, the body’s immune system attacks the brain, leading to long-term damage. While MS has been thought to primarily affect white matter in the brain, this research shows that it could also damage particularly vulnerable CUX2 neurons in the gray matter.This damage may help explain why people with MS can experience memory problems and cognitive decline as the disease progresses.“The CUX2 neurons are like a ‘canary in the coal mine’ for the brain affected by MS,” said David Rowitch, MD, PhD, co-corresponding author of both studies, deputy director for Research at Guerin Children’s, and professor of Paediatrics at the University of Cambridge. “They are early warning signs of trouble. If we can protect these cells, we might be able to contain the damage before disease progresses.”

For years, scientists have suspected that the gut plays a role in Multiple Sclerosis (MS), but the “smoking gun” linking the two has been elusive. A landmark study has finally identified the cellular mechanism: Intestinal Epithelial Cells (IECs)—the cells lining your gut—are acting as “accidental” messengers.The study found that in patients with MS, these gut cells abnormally express MHC II, a protein that “presents” antigens to the immune system. This interaction mistakenly transforms ordinary immune cells into pathogenic Th17 cells, which then migrate from the gut directly to the central nervous system to attack the brain and spinal cord.

Researchers from UC San Francisco, the University of Cambridge, and Cedars-Sinai Medical Center now report that this loss is linked to DNA damage inside neurons, driven by inflammation in the brain. The discovery helps explain why scans of people with MS show injury not only in white matter, which carries signals, but also in gray matter, where brain cells reside. It also points to new treatment possibilities.

A gene on the X chromosome revs up inflammation in the female brain, which may explain why rates of multiple sclerosis are higher in women than in men, scientists suggest.

Progressive multiple sclerosis (PMS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by relentless progression and limited treatment options. Recent studies have highlighted the role of B cells and plasma cells in driving PMS but current therapies face challenges in targeting cells within the CNS. Now, writing in Cell, Qin et al. present a first-in-human study of anti-B cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy in five patients with PMS, showing a favourable safety profile and potential therapeutic benefits.

Près de deux millions de personnes dans le monde souffrent de cette maladie invalidante. Les symptômes varient énormément, et il n'y a aucun remède connu à ce jour.